Search
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis … [A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.
Products: ERBITUX 5MG/ML SOLUTION FOR INFUSIONTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalMarketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.
Categories: Antihypertensive Agents Indicated for HypertensionProducts: ALDACTONE A, SPIRONOLACTON AL 50Levobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnIn particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. … It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal
Synonyms: L-BUPIVACAINE, L-(−)-bupivacaineRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: MABTHERA ROCHE SOLUCION PARA INFUSION 10 MG/ML, Mabthera Concentrate for Solution for Infusion 100mg/10mlTechnetium Tc-99m exametazime
go.drugbank.com/drugs/DB09163ApprovedExametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope. … It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease.
Categories: Compounds used in a research, industrial, or household settingDidanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalThis modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. … A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalA non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. … Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Products: Vecuronium Bromide for Injection, VECURONIUM BROMIDE FOR INJECTIONAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML